The European Commission (EC) has approved the use and marketing in Europe of Rixathon, a biosimilar to Roche’s MabThera (rituximab). The decision follows a positive review of Rixathon by the Committee for Medicinal Products for Human Use (CHMP) last April in response to Sandoz’s marketing application.
News
News
Nucala Triggered Remission in Eosinophilic Granulomatosis with Polyangiitis, But Not All Benefit
Nucala (mepolizumab) effectively induced remission in about half of patients with eosinophilic granulomatosis with polyangiitis (EGPA) that relapsed or did not respond to treatment, according to results from a Phase 3 clinical trial (NCT02020889). The study found that Nucala reduced…
Recent Posts
- Blood cancer drug aids kidney recovery in 2 AAV patients, study shows
- AAV relapse linked to distinct gene activity signature in blood, study says
- The ability to recalculate is like GPS for managing ANCA vasculitis
- Developers partner on infusion therapy for vasculitis with kidney damage
- Why we need greater transparency in prescription drug pricing